Dumping Syndrome Market Outlook, Insights, and Overview 2024-2033

"The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.

Dumping Syndrome Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.

The Market Size Is Expected To Reach $1.81 billion In 2028 At A CAGR Of 9.9% :

The dumping syndrome market size has grown rapidly in recent years. It will grow from $1.12 billion in 2023 to $1.24 billion in 2024 at a compound annual growth rate (CAGR) of 10.9%. The growth in the historic period can be attributed to gastric surgery procedures, increased prevalence of obesity, advancements in surgical techniques, improved diagnostic methods.

The dumping syndrome market size is expected to see strong growth in the next few years. It will grow to $1.81 billion in 2028 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to weight loss surgery trends, personalized treatment approaches, nutritional and dietary interventions, telemedicine and remote monitoring. Major trends in the forecast period include minimally invasive surgical techniques, data analytics and ai, increased collaboration, preventive measures.

Request A Sample Of This Report - https://www.thebusinessresearchcompany.com/sample.aspx?id=12991&type=smp

Dumping Syndrome Market Major Segments
The dumping syndrome market covered in this report is segmented -

1) By Diagnosis: Blood Sugar Test; Gastric Emptying Test; Medical History; Other Diagnosis
2) By Treatment: Medication; Surgery; Other Treatments
3) By Route Of Administration: Oral; Intravenous; Other Routes Of Administration
4) By Phase: Early Dumping Phase; Late Dumping Phase
5) By End User: Hospitals And Clinics; Research Laboratories; Other End Users

Key Driver - Increasing Incidence Of Upper Gi Diseases Boosts The Dumping Syndrome Market

The rising prevalence of upper GI diseases is expected to propel the growth of the dumping syndrome market going forward. Upper gastrointestinal (GI) diseases refer to disorders affecting the upper part of the digestive system, including the esophagus, stomach and the first part of the small intestine (duodenum). Dumping syndrome is a condition that can occur after a person undergoes particular upper gastrointestinal (GI) surgeries, particularly those that involve the stomach, duodenum, or pyloric sphincter. For instance, in April 2023, according to the National Library of Medicine, a US-based medical library, Upper gastrointestinal bleeding (UGIB) is a frequent issue, with an estimated occurrence in 80 to 150 out of 100,000 individuals annually. The estimated mortality rates range from 2 to 15 percent. Upper gastrointestinal bleeding (UGIB) constitutes 75% of all cases of acute gastrointestinal (GI) bleeding. Therefore, the rising prevalence of upper GI diseases is driving the growth of the dumping syndrome market.

Customise This Report As Per Your Requirements - https://www.thebusinessresearchcompany.com/Customise?id=12991&type=smp

Prominent Trend - Innovative Non-Invasive Tools Revolutionizing Gastric Emptying Measurement In The Dumping Syndrome Market

Major companies operating in the dumping syndrome market are increasing their focus on introducing non-invasive tools for measuring gastric emptying to gain a competitive edge in the market. Non-invasive tools for measuring gastric emptying are diagnostic methods that assess the rate at which the stomach empties its contents into the small intestine without the need for invasive procedures. For instance, in September 2021, Cairn Diagnostics, a US-based life science company, launched the 13C-Spirulina Gastric Emptying Breath Test (GEBT). The test involves consuming a small amount of Spirulina labeled with a stable isotope of carbon, followed by breathing into a machine that measures the amount of carbon dioxide in the breath. The rate of carbon dioxide production is then used to calculate the rate of food emptying from the stomach. The GEBT is a safe, standardized, and convenient alternative to nuclear medicine-based gastric emptying evaluations typically conducted in a nuclear medicine center. The test can be administered in a clinical setting or via telehealth at a patient's home and is a non-invasive tool for measuring gastric emptying velocity and aiding in the diagnosis of gastroparesis.

Innovative Endoscopy Systems like EVIS X1 Revolutionize Diagnosis and Treatment of Dumping Syndrome

Companies operating in the dumping syndrome market are adopting new technological solutions, such as EVIS X1 to sustain their position in the market. The EVIS X1 endoscopy system features three new enhancements designed to assist physicians in visualizing GI bleeds and anatomical structures. For instance, in April 2020, Olympus Corporation, a Japan-based equipment and tools manufacturing company for optical and digital technologies launched EVIS X1. EVIS X1 promotes accurate screening and confident diagnosis in the identification, characterization and management of gastrointestinal problems including colorectal cancer (CRC) or bronchial diseases. These include narrow-band imaging (NBI), red dichromatic imaging (RDI), texture and color enhancement imaging (TXI) and extended depth of field (EDOF).

Dumping Syndrome Market Players
Major players in the dumping syndrome market are Cardinal Health Inc., Johnson & Johnson Private Limited, Abbott Laboratories Inc., Medtronic PLC, Covidien PLC, Fujifilm Holdings Corporation, Stryker Corporation, Allergan PLC, Boston Scientific Corporation, B. Braun Melsungen AG, Olympus Corporation, Intuitive Surgical Inc., Terumo Corporation, Steris Corporation, Teleflex Medical Europe Ltd., Cook Medical Inc., Karl Storz SE & Co. KG, Conmed Corporation, Applied Medical Resources Corporation, Richard Wolf GmbH, Pentax Medical Company, GI Dynamics, EndoGastric Solutions Inc., Apollo Endosurgery Inc., EndoChoice Holdings Inc., Cousin Biotech , Mediflex Surgical Product, Asensus Surgical Inc., USGI Medical Inc., TransEnterix Inc.

View The Full Report Here - https://www.thebusinessresearchcompany.com/report/dumping-syndrome-global-market-report

Largest And Fastest Growing Region In The Market
North America was the largest region in the dumping syndrome market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in dumping syndrome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Dumping Syndrome Market Report Structure
3. Dumping Syndrome Market Trends And Strategies
4. Dumping Syndrome Market - Macro Economic Scenario
5. Dumping Syndrome Market Size And Growth
…..
27. Dumping Syndrome Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

"Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide."

This release was published on openPR.